A Dose-Escalation Vaccine Trial In HER2-Overexpressing Patients With High-Risk Breast Cancer

This study is ongoing, but not recruiting participants.

Study NCT00058526 Information provided by GlaxoSmithKline

First Received: April 7, 2003 Last Updated: September 27, 2006 History of Changes

No Study Results Posted for this Study

Study Status:	This study is ongoing, but not recruiting participants.
Estimated Study Completion Date:	No date given
Estimated Primary Completion Date:	No date given